BioCryst Reports Second Quarter 2026 Financial Results
BioCryst reported Q2 2026 total net revenue of $218.3 million, up 34% year-over-year, with ORLADEYO contributing $158.2 million. The company generated positive free cash flow and achieved a GAAP operating profit of $98.5 million, prompting a raise in full-year total revenue guidance to $690 million to $715 million.
Key figures
- Eps
- 0.3
- Revenue
- 218300000
- Guidance
- FY2026 total revenue $690M-$715M (raised from $635M-$660M); ORLADEYO revenue $625M-$645M (maintained)
- Revenue Yoy
- 34%
- Cash position
- 354000000
- Orladeyo revenue
- 158200000
- Gaap operating profit
- 98500000
- Non gaap operating profit
- 113200000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.